There were 324 press releases posted in the last 24 hours and 157,725 in the last 365 days.

Dynavax to Webcast Cancer R&D Day on December 9, 2016

/EINPresswire.com/ -- BERKELEY, CA--(Marketwired - December 01, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional investors, will be webcast live and can be found in the Investor section of the company's website at www.dynavax.com.

The webcast of the presentations and Q&A will begin at 8:30 a.m. EST on Friday, December 9, 2016 and is scheduled to conclude at 11:00 a.m. EST. Presentations will be made by senior executives of Dynavax and will also feature two world-renowned experts in immuno-oncology:

  • Ezra Cohen, M.D., Professor, Division of Hematology/Oncology, Department of Medicine; Associate Director for Translational Science; Co-leader, Solid Tumor Therapeutics Program, UC San Diego Moores Cancer Center
  • Antoni Ribas, M.D., Professor of Medicine, Professor of Surgery and Professor of Molecular and Medical Pharmacology at University of California Los Angeles (UCLA); Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center and the Chair of the Melanoma Committee at SWOG

About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com.

Contact:
Michael Ostrach
Chief Financial Officer
510-665-7257
Email contact

Distribution channels: Healthcare & Pharmaceuticals